US2017151182A1PendingUtilityA1

Treatment of schizophrenia using beta-caryophyllene and cb2 receptor agonists

50
Assignee: ARIEL SCIENT INNOVATIONS LTDPriority: Mar 19, 2012Filed: Feb 14, 2017Published: Jun 1, 2017
Est. expiryMar 19, 2032(~5.7 yrs left)· nominal 20-yr term from priority
Inventors:Sharon Anavi-GofferJuerg Gertsch
A61P 43/00A61P 25/18A61K 9/48A61K 9/0053A61K 45/06A61K 31/4515A61K 9/0019A61K 31/015A61K 47/20A61K 31/519A61K 31/5513A61K 31/5415
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Disclosed are compositions comprising beta-caryophyllene (BCP) for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using BCP. Disclosed are also compositions comprising CB2 receptor agonists for use in the treatment of schizophrenia, methods of making such compositions and methods of treating schizophrenia using CB2 receptor agonists.

Claims

exact text as granted — not AI-modified
1 . A composition comprising beta-caryophyllene (BCP) and a pharmaceutically effective carrier for use in treating schizophrenia. 
     
     
         2 . The composition of  claim 1 , wherein said schizophrenia is selected from the group consisting of paranoid schizophrenia; disorganized schizophrenia; undifferentiated schizophrenia; catatonic schizophrenia; and residual schizophrenia. 
     
     
         3 . The composition of any of  claims 1  to  2 , wherein said treating comprises treating at least one symptom of schizophrenia selected from the group consisting of a negative symptom of schizophrenia and a positive symptom of schizophrenia. 
     
     
         4 . The composition of any of  claims 1  to  3 , wherein said pharmaceutically effective carrier comprises dimethyl sulfoxide (DMSO). 
     
     
         5 . The composition of any of  claims 1  to  4 , a single discrete unit of the composition comprises BCP at a weight in the range of from about 25 to about 100 mg. 
     
     
         6 . The composition of any of  claims 1  to  5 , formulated as an injectable solution dosage form. 
     
     
         7 . The composition of any one of  claims 1  to  5 , wherein the composition is formulated as an orally-administrable dosage form. 
     
     
         8 . The composition of any of  claims 1  to  7 , further comprising at least one additional antipsychotic agent. 
     
     
         9 . The composition of  claim 8 , wherein said at least one additional antipsychotic agent is selected from the group consisting of chlorpromazine, haloperidol, perphenazine, fluphenazine, clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and paliperidone, or combinations thereof. 
     
     
         10 . Use of beta-caryophyllene (BCP) and a pharmaceutically effective carrier in the manufacture of a composition for treating schizophrenia in a subject in need thereof. 
     
     
         11 . The use according to  claim 10 , wherein said schizophrenia is selected from the group consisting of paranoid schizophrenia; disorganized schizophrenia; undifferentiated schizophrenia; catatonic schizophrenia; and residual schizophrenia. 
     
     
         12 . The use according to any of  claims 10  to  11 , wherein said treating comprises treating at least one symptom of schizophrenia selected from the group consisting of a negative symptom of schizophrenia and a positive symptom of schizophrenia. 
     
     
         13 . The use of any of  claims 10  to  12 , wherein said pharmaceutically effective carrier comprises dimethyl sulfoxide (DMSO). 
     
     
         14 . The use according to any of  claims 10  to  13 , wherein a single discrete unit of said composition comprises BCP at a weight in the range of from about 25 to about 100 mg. 
     
     
         15 . The use according to any of  claims 10  to  14 , wherein said composition is made as an injectable solution dosage form. 
     
     
         16 . The use according to any of  claims 10  to  14 , wherein said composition is made as an orally administrable dosage form. 
     
     
         17 . The use according to any of  claims 10  to  16 , wherein said composition further comprises at least one additional antipsychotic agent. 
     
     
         18 . The use according to  claim 17 , wherein said at least one additional antipsychotic agent is selected from the group consisting of chlorpromazine, haloperidol, perphenazine, fluphenazine, clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and paliperidone, or combinations thereof. 
     
     
         19 . A method for treating schizophrenia in a subject in need thereof, the method comprising administering a therapeutic composition comprising beta-caryophyllene (BCP) and a pharmaceutically effective carrier. 
     
     
         20 . The method of  claim 19 , wherein said schizophrenia is selected from the group consisting of paranoid schizophrenia; disorganized schizophrenia; undifferentiated schizophrenia; catatonic schizophrenia; and residual schizophrenia. 
     
     
         21 . The method of any of  claims 19  to  20 , wherein said treating comprises treating at least one symptom of schizophrenia selected from the group consisting of a negative symptom of schizophrenia and a positive symptom of schizophrenia. 
     
     
         22 . The method of any of  claims 19  to  21 , wherein an average daily amount of said BCP administered is from about 0.4 mg/kg to about 2 mg/kg. 
     
     
         23 . The method of any of  claims 19  to  22 , wherein said pharmaceutically effective carrier comprises dimethyl sulfoxide (DMSO). 
     
     
         24 . The method of any of  claims 19  to  23 , wherein said administering comprises injecting said composition to said subject. 
     
     
         25 . The method of any of  claims 19  to  23 , wherein said administering comprises orally administering said composition to said subject. 
     
     
         26 . The method of any of  claims 19  to  25 , further comprising co-administering at least one additional antipsychotic agent. 
     
     
         27 . The method of  claim 26 , wherein said at least one additional antipsychotic agent is selected from the group consisting of chlorpromazine, haloperidol, perphenazine, fluphenazine, clozapine, risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, and paliperidone, or combinations thereof. 
     
     
         28 . The method of any of  claims 26  to  27 , wherein said at least one additional antipsychotic agent is co-administered in a single dosage form together with said BCP. 
     
     
         29 . The method of any of  claims 26  to  27 , wherein said at least one additional antipsychotic agent is co-administered in a dosage form separate from said BCP. 
     
     
         30 . A composition comprising a CB2 receptor agonist and a pharmaceutically effective carrier for use in treating schizophrenia. 
     
     
         31 . Use of a composition comprising a CB2 receptor agonist and a pharmaceutically effective carrier in the manufacture of a composition for treating schizophrenia in a subject in need thereof. 
     
     
         32 . A method for the treating schizophrenia in a subject in need thereof, the method comprising administering a therapeutic composition comprising a CB2 receptor agonist and a pharmaceutically effective carrier.

Join the waitlist — get patent alerts

Track US2017151182A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.